Krystal Biotech said IOLITE enrollment for KB803 is complete and it remains on track for KB803 and KB801 registrational data readouts in 2026. The company also reported FDA platform technology designations for KB407 and KB111 and continued VYJUVEK expansion.
Krystal Biotech posted Q4 2025 net revenue of $107.1 million from Vyjuvek sales, with full-year revenue reaching $389.1 million. The company expanded to over 90 patients across Germany, France, and Japan while advancing its pipeline with new FDA designations.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07717346 |
A Study to Investigate Safety and Efficacy of KB111 for the Treatment of Hailey-Hailey Disease |
RECRUITING | EARLY_PHASE1 |
